iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine
Catherine Bollard et al.
Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
The future is bright for hematological oncology: promising areas for 2018 and beyond